MaaT Pharma
MAAT | PA
Overview
Corporate Details
- ISIN(s):
- FR0012634822 (+1 more)
- LEI:
- 969500CQQB6XUNW6CN97
- Country:
- France
- Address:
- 70 AVENUE TONY GARNIER, 69007 LYON
- Website:
- https://www.maatpharma.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Building a leading microbiome company in oncology MaaT Pharma has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-07-28 07:30 |
Capital/Financing Update
Informations privilégiées / Autres communiqués
|
French | 158.6 KB | |
| 2025-07-28 07:30 |
Capital/Financing Update
Inside Information / Other news releases
|
English | 106.4 KB | |
| 2025-06-13 07:30 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 127.5 KB | |
| 2025-06-13 07:30 |
Earnings Release
Inside Information / Other news releases
|
English | 151.0 KB | |
| 2025-06-02 18:30 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 135.6 KB | |
| 2025-06-02 18:30 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 166.2 KB | |
| 2025-05-14 18:00 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 121.4 KB | |
| 2025-05-14 18:00 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 117.5 KB | |
| 2025-05-14 07:30 |
Pre-Annual General Meeting Information
Inside Information / Other news releases
|
English | 71.4 KB | |
| 2025-05-14 07:30 |
Pre-Annual General Meeting Information
Informations privilégiées / Autres communiqués
|
French | 147.0 KB | |
| 2025-05-13 18:00 |
Earnings Release
Informations privilégiées / Autres communiqués
|
French | 131.8 KB | |
| 2025-05-13 18:00 |
Earnings Release
Inside Information / Other news releases
|
English | 118.8 KB | |
| 2025-05-12 07:30 |
Earnings Release
Informations privilégiées / Autres communiqués
|
French | 140.1 KB | |
| 2025-05-12 07:30 |
Regulatory News Service
Inside Information / Other news releases
|
English | 861.7 KB | |
| 2025-04-28 18:00 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 958.7 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-12 | N/A | Other | Sell | 8 | 60.87 EUR |
| 2024-07-11 | N/A | Other | Sell | 57 | 436.14 EUR |
| 2023-12-22 | N/A | Other | Buy | 2,940 | 14,994.00 EUR |
| 2023-12-22 | N/A | Other | Buy | 1,960 | 9,996.00 EUR |
| 2023-09-27 | N/A | Other | Buy | 500 | 3,050.00 EUR |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Kamada Ltd. | Israel | KMDA | |
|
Kancera | Sweden | KAN | |
|
Kuros Biosciences Ltd. | Switzerland | KURN | |
|
Lidds AB | Sweden | LIDDS | |
|
Lifecare ASA | Norway | LIFE | |
|
Lineage Cell Therapeutics Inc. | Israel | LCTX | |
|
Lipidor AB | Sweden | LIPI | |
|
Lipigon Pharmaceuticals AB | Sweden | LPGO | |
|
Lipum AB | Sweden | LIPUM | |
|
Lonza Group AG | Switzerland | LONN |